Beam Therapeutics annual return on assets (roa)
2020
2021
2022
2023
2024
2025
Beam Therapeutics Return on Assets (ROA) Growth & History (BEAM)
Beam Therapeutics's return on assets (roa) was −6.19% for fiscal 2025.
View full Beam Therapeutics company overviewBeam Therapeutics annual return on assets (roa) history
| Fiscal year | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −6.19% | +23.20 pp |
| 2024 | 2024-12-31 | −29.39% | −19.93 pp |
| 2023 | 2023-12-31 | −9.46% | +11.07 pp |
| 2022 | 2022-12-31 | −20.53% | +17.95 pp |
| 2021 | 2021-12-31 | −38.49% | +25.55 pp |
| 2020 | 2020-12-31 | −64.03% | — |
Beam Therapeutics quarterly return on assets (roa)
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −6.23% | +23.74 pp |
| Q1 2026 | 2026-03-31 | −4.48% | +22.86 pp |
| Q4 2025 | 2025-12-31 | −6.19% | +23.20 pp |
| Q3 2025 | 2025-09-30 | −33.32% | −21.65 pp |
| Q2 2025 | 2025-06-30 | −29.97% | −19.03 pp |
| Q1 2025 | 2025-03-31 | −27.34% | −17.33 pp |
| Q4 2024 | 2024-12-31 | −29.39% | −19.93 pp |
| Q3 2024 | 2024-09-30 | −11.67% | +12.09 pp |
| Q2 2024 | 2024-06-30 | −10.94% | +12.67 pp |
| Q1 2024 | 2024-03-31 | −10.01% | +12.70 pp |
| Q4 2023 | 2023-12-31 | −9.46% | +11.07 pp |
| Q3 2023 | 2023-09-30 | −23.76% | +1.41 pp |
| Q2 2023 | 2023-06-30 | −23.60% | −3.36 pp |
| Q1 2023 | 2023-03-31 | −22.71% | −0.51 pp |
| Q4 2022 | 2022-12-31 | −20.53% | +17.95 pp |
| Q3 2022 | 2022-09-30 | −25.17% | +30.78 pp |
| Q2 2022 | 2022-06-30 | −20.25% | +48.10 pp |
| Q1 2022 | 2022-03-31 | −22.20% | +49.79 pp |
| Q4 2021 | 2021-12-31 | −38.49% | +25.55 pp |
| Q3 2021 | 2021-09-30 | −55.95% | — |
| Q2 2021 | 2021-06-30 | −68.35% | — |
| Q1 2021 | 2021-03-31 | −72.00% | — |
| Q4 2020 | 2020-12-31 | −64.03% | — |
Beam Therapeutics return on assets (roa) trends
Over the last five fiscal years, Beam Therapeutics's return on assets (roa) increased from −64.03% to −6.19%, a change of +57.85 percentage points. The latest reported quarter, Q2 2026, shows −6.23%.
About the metric
What return on assets means
Return on assets measures profit relative to the assets used to generate it. It can help compare operating efficiency over time, although normal ROA differs substantially between asset-light and asset-intensive industries.
Calculation and source
How return on assets is calculated
TickerStat calculates annual ROA as reported net income divided by average total assets. Quarterly observations use trailing-12-month net income and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...